Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 10, 2008, Pages 3853-3859

  Neggers, Sebastian J C M M ^a   Van Aken, M O ^a   De Herder, W W ^a   Feelders, R A ^a   Janssen, J A M J L ^a   Badia, X ^b   Webb, S M ^c   Van Der Lely, A J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PEGVISOMANT; PLACEBO; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; HEALTH STATUS; HUMAN; LONG TERM CARE; MALE; METABOLIC PARAMETERS; MONOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SWEATING;

EID: 53749104459     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-0669     Document Type: Article

References (30)

1. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, van der Lely AJ 2005 Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365:1644-1646
2. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177
3. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO 2001 Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759
4. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ 2007 Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 92:4598-4601
5. Beauregard C, Truong U, Hardy J, Serri O 2003 Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 58:86-91
6. Holdaway IM, Rajasoorya CR, Gamble GD, Stewart AW 2003 Long-term treatment outcome in acromegaly. Growth Horm IGF Res 13:185-192
7. Holdaway IM, Rajasoorya RC, Gamble GD 2004 Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667-674
8. Swearingen B, Barker FG, 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419-3426
9. Hua SC, Yan YH, Chang TC 2006 Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur J Endocrinol 155:831-837
10. Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F 2005 Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 90:2731-2739
11. Biermasz NR, van Thiel SW, Pereira AM, Hoftijzer HC, van Hemert AM, Smit JW, Romijn JA, Roelfsema F 2004 Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 89:5369-5376
12. Bonapart IE, van Domburg R, ten Have SM, de Herder WW, Erdman RA, Janssen JA, van der Lely AJ 2005 The 'bio-assay' quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations. Eur J Endocrinol 152:217-224
13. Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ 2005 Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. J Clin Endocrinol Metab 90:3337-3341
14. Webb SM, Prieto L, Badia X, Albareda M, Catala M, Gaztambide S, Lucas T, Paramo C, Pico A, Lucas A, Halperin I, Obiols G, Astorga R 2002 Acromegaly Quality of Life Questionnaire(ACROQOL)a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol (Oxf) 57:251-258
15. Leung KC, Doyle N, Ballesteros M, Waters MJ, Ho KK 2000 Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J Clin Endocrinol Metab 85:4712-4720
16. Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S 2004 Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest 114:349-356
17. Elmlinger MW, Kuhnel W, Weber MM, Ranke MB 2004 Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med 42:654-664
18. Granada ML, Ulied A, Casanueva FF, Pico A, Lucas T, Torres E, Sanmarti A 2007 Serum IGF-I measured by four different immunoassays in patients with adult GH deficiency or acromegaly and in a control population. Clin Endocrinol (Oxf) 68:942-950
19. Badia X, Webb SM, Prieto L, Lara N 2004 Acromegaly Quality of Life Questionnaire (AcroQoL). Health Qual Life Outcomes 2:13
20. Webb SM 2006 Quality of life in acromegaly. Neuroendocrinology 83:224-229
21. Paisley AN, Rowles SV, Roberts ME, Webb SM, Badia X, Prieto L, Shalet SM, Trainer PJ 2007 Treatment of acromegaly improves quality of life, measured by AcroQol. Clin Endocrinol (Oxf) 67:358-362
22. Segev Y, Landau D, Rasch R, Flyvbjerg A, Phillip M 1999 Growth hormone receptor antagonism prevents early renal changes in nonobese diabetic mice. J Am Soc Nephrol 10:2374-2381
23. Growth Hormone Research Society, Pituitary Society 2004 Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society. J Clin Endocrinol Metab 89:3099-3102
24. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S 2000 Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526-529
25. Bengtsson BA, Brummer RJ, Eden S, Bosaeus I, Lindstedt G 1989 Body composition in acromegaly: the effect of treatment. Clin Endocrinol (Oxf) 31:481-490
26. Hansen TK, Moller J, Thomsen K, Frandsen E, Dall R, Jorgensen JO, Christiansen JS 2001 Effects of growth hormone on renal tubular handling of sodium in healthy humans. Am J Physiol Endocrinol Metab 281:E1326-E1332
27. Moller J, Nielsen S, Hansen TK 1999 Growth hormone and fluid retention. Horm Res 51(Suppl 3):116-120
28. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LO, Hagen C, Orskov H 2005 Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 90:5627-5631
29. Linde L, Sorensen J, Ostergaard M, Horslev-Peterson K, Hetland ML 2008 Health-related quality of life: validity, reliability, and responsiveness of SF-36, EQ-15D, EQ-5D RAQoL, and HAQ in patients with rheumatoid arthritis. J Rheumatol 35:1528-1537
30. Keenan AM, McKenna SP, Doward LC, Conaghan PG, Emery P, Tennant A 2008 Development and validation of a needs-based quality of life instrument for osteoarthritis. Arthritis Rheum 59:841-848